These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32803970)

  • 1. Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
    Reßing N; Sönnichsen M; Osko JD; Schöler A; Schliehe-Diecks J; Skerhut A; Borkhardt A; Hauer J; Kassack MU; Christianson DW; Bhatia S; Hansen FK
    J Med Chem; 2020 Sep; 63(18):10339-10351. PubMed ID: 32803970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel HDAC6 selective inhibitors with 4-aminopiperidine-1- carboxamide as the core structure enhanced growth inhibitory activity of bortezomib in MCF-7 cells.
    Zhao C; Gao J; Zhang L; Su L; Luan Y
    Biosci Trends; 2019; 13(1):91-97. PubMed ID: 30867374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine.
    Tretbar M; Schliehe-Diecks J; von Bredow L; Tan K; Roatsch M; Tu JW; Kemkes M; Sönnichsen M; Schöler A; Borkhardt A; Bhatia S; Hansen FK
    Eur J Med Chem; 2024 Jun; 272():116447. PubMed ID: 38714044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
    Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y
    Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
    Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C
    Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
    Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
    Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
    Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
    Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
    Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
    Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
    Brindisi M; Senger J; Cavella C; Grillo A; Chemi G; Gemma S; Cucinella DM; Lamponi S; Sarno F; Iside C; Nebbioso A; Novellino E; Shaik TB; Romier C; Herp D; Jung M; Butini S; Campiani G; Altucci L; Brogi S
    Eur J Med Chem; 2018 Sep; 157():127-138. PubMed ID: 30092367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
    Vögerl K; Ong N; Senger J; Herp D; Schmidtkunz K; Marek M; Müller M; Bartel K; Shaik TB; Porter NJ; Robaa D; Christianson DW; Romier C; Sippl W; Jung M; Bracher F
    J Med Chem; 2019 Feb; 62(3):1138-1166. PubMed ID: 30645113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
    Osko JD; Porter NJ; Narayana Reddy PA; Xiao YC; Rokka J; Jung M; Hooker JM; Salvino JM; Christianson DW
    J Med Chem; 2020 Jan; 63(1):295-308. PubMed ID: 31793776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation.
    Relitti N; Saraswati AP; Chemi G; Brindisi M; Brogi S; Herp D; Schmidtkunz K; Saccoccia F; Ruberti G; Ulivieri C; Vanni F; Sarno F; Altucci L; Lamponi S; Jung M; Gemma S; Butini S; Campiani G
    Eur J Med Chem; 2021 Feb; 212():112998. PubMed ID: 33199154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
    Zhang XH; Kang HQ; Tao YY; Li YH; Zhao JR; Ya-Gao ; Ma LY; Liu HM
    Eur J Med Chem; 2021 Jun; 218():113392. PubMed ID: 33831778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma.
    Peng X; Li L; Chen J; Ren Y; Liu J; Yu Z; Cao H; Chen J
    J Med Chem; 2022 Feb; 65(3):2434-2457. PubMed ID: 35043615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of 2-quinolineacrylamides.
    Wang SW; Lin MH; Hsu FC; Chen MC; Liou JP; Liu YT; Chen SS; Lee HY
    Bioorg Med Chem; 2020 Feb; 28(3):115250. PubMed ID: 31924504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
    Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP
    Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.